Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway

Resistance to BRAF Inhibition in Melanomas

(2011) David B. Solit et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Norcantharidin induces cell cycle arrest and inhibits progression of human leukemic Jurkat T cells through mitogen-activated protein kinase-mediated regulation of interleukin-2 production

(2010) Hui-Fen Liao et al.   TOXICOLOGY IN VITRO

Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action

(2009) Yan Huang et al.   CYTOTECHNOLOGY

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

Akt phosphorylates the TR3 orphan receptor and blocks its targeting to the mitochondria

(2008) H.-Z. Chen et al.   CARCINOGENESIS